On an autumn day of 2025, WuXi AppTec’s Research Chemistry Services (RCS) received an email from a customer: they needed to design and synthesize a bioactive target molecule but were stuck at a key intermediate step, and using conventional routes was hard to move forward...

Trust isn’t built in a day. It grows slowly, project by project, with consistent quality and efficiency. At WuXi AppTec, this is what everyday collaboration looks like: teams and clients achieving more together...

Radionuclide drug conjugates (RDCs) have recently emerged as a promising approach in oncology, attracting increasing attention. By integrating precision diagnosis with targeted therapy, RDCs offer a new therapeutic paradigm for cancer patients. As of the end of 2025, 11 RDC drugs have been approved globally, validating their clinical value and potential...

Oligonucleotides represent a rapidly emerging modality. As the technology evolves, extrahepatic delivery is becoming a new trend, with the potential to expand oligonucleotide-based therapies into a broader range of disease areas. Lipid conjugation, as one of the key approaches for achieving extrahepatic delivery, still presents considerable challenges during the transition from laboratory to clinical development...

New drug development involves long timelines and multiple steps. Each step is critical and full of uncertainties, and challenges sometimes come precisely from the steps that are easily overlooked...

Several years ago, WuXi STA, a subsidiary of WuXi AppTec, undertook a process optimization assignment for a client...